RSB Spine v. Innovasis: Spinal Implant Patent Dismissed With Prejudice in 184 Days
RSB Spine filed an infringement action in the Utah District Court targeting Innovasis’s Ax® Stand-Alone ALIF System under US9713537B2, a patent covering spinal fusion implant technology. The plaintiff voluntarily dismissed its complaint with prejudice under Rule 41(a)(1)(A)(i) after just 184 days — a timeline that typically signals a negotiated resolution or a strategic withdrawal before substantive litigation costs mounted.
RSB Spine’s ALIF Patent Claim Ends Quickly — With Finality
On April 10, 2024, RSB Spine initiated an infringement action against spinal device manufacturer Innovasis in the United States District Court for the District of Utah, presided over by Judge David Barlow. The complaint alleged that Innovasis’s Ax® Stand-Alone ALIF (Anterior Lumbar Interbody Fusion) System infringed US9713537B2, a patent directed at spinal implant technology filed under application number US15/413945. RSB Spine was represented by Proskauer Rose, LLP and Snell & Wilmer, LLP — a pairing that suggests a well-resourced enforcement strategy from the outset.
The case closed on October 11, 2024, just 184 days after filing. RSB Spine invoked Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure to file a notice of voluntary dismissal with prejudice. A dismissal with prejudice is legally final: RSB Spine permanently extinguishes its right to bring the same patent infringement claims against Innovasis based on US9713537B2. Innovasis, for its part, faces no ongoing litigation exposure from this action on these specific claims.
The speed of resolution — under six months — and the unusual choice of dismissal with prejudice (rather than without) is commercially significant. Voluntary dismissals with prejudice before any substantive ruling often suggest either a confidential settlement in which the plaintiff received consideration, or an internal reassessment of claim strength following early discovery or pre-trial motions. The public record does not disclose any settlement terms, license agreement, or fee award, leaving the precise commercial outcome undisclosed.
Filing to Dismissed with Prejudice in 184 days
184 days — resolved well below the median district court patent litigation cycle of 2–3 years
Dismissed with prejudice: what the Rule 41 exit means for both parties
Rule 41 dismissal with prejudice — a permanent close
Under Rule 41(a)(1)(A)(i), a plaintiff may dismiss without a court order before the opposing party serves an answer or a motion for summary judgment. Electing to do so ‘with prejudice’ — rather than the default without prejudice — is an irreversible step: it operates as a judgment on the merits and permanently bars RSB Spine from re-asserting these infringement claims against Innovasis under US9713537B2. Courts treat it as claim preclusion.
Rule 41(a)(1)(A)(i) — merits-bar triggeredRSB Spine forfeits future claims — likely in exchange for consideration
By accepting a with-prejudice dismissal, RSB Spine permanently surrendered its infringement case against Innovasis on US9713537B2. This is an unusual concession unless value was exchanged — most commonly a confidential license payment, a cross-license, or a covenant not to sue from Innovasis. The public record is silent on terms. RSB Spine retains US9713537B2 and may still enforce it against other parties not covered by any agreement reached here.
Claims extinguished — no public consideration disclosedInnovasis obtains permanent freedom from this claim
The with-prejudice dismissal gives Innovasis a clean legal shield: RSB Spine cannot revive this specific infringement action under US9713537B2. The Ax® Stand-Alone ALIF System continues without the cloud of this litigation. Whether Innovasis secured a formal license or simply benefited from the plaintiff’s withdrawal is unknown from the public record, but the commercial outcome — certainty of non-exposure — is the same either way.
Innovasis Ax® ALIF — litigation risk clearedSpinal fusion IP enforcement: a pattern of quick resolutions
Sub-six-month resolutions in medical device patent cases — particularly with prejudice — consistently suggest either strong early leverage by the defendant or a negotiated exit. For competitors in the ALIF and stand-alone interbody fusion space, US9713537B2 remains active and potentially enforceable against other products. Manufacturers of competing ALIF systems should treat this case as a signal that RSB Spine is actively monitoring its portfolio, even if this specific action concluded quickly.
ALIF market — patent enforcement risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | RSB Spine | Individual | Spinal implant IP licensor — holder of US9713537B2 covering ALIF fusion technologySearch in Eureka ↗ |
| Defendant | Innovasis | Individual | Innovasis — spinal device manufacturer, maker of the Ax® Stand-Alone ALIF SystemSearch in Eureka ↗ |
| Plaintiff counsel | Baldassare Vinti | Attorney | Counsel for RSB SpineSearch in Eureka ↗ |
| Plaintiff counsel | Elizabeth Shrieves | Attorney | Counsel for RSB SpineSearch in Eureka ↗ |
| Plaintiff counsel | Erik B. Milch | Attorney | Counsel for RSB SpineSearch in Eureka ↗ |
| Plaintiff counsel | Joseph M. Drayton | Attorney | Counsel for RSB SpineSearch in Eureka ↗ |
| Plaintiff counsel | Mark O. Morris | Attorney | Counsel for RSB SpineSearch in Eureka ↗ |
| Plaintiff counsel | Sarah W. Ghivizzani | Attorney | Counsel for RSB SpineSearch in Eureka ↗ |
| Plaintiff law firm | Proskauer Rose, LLP | Law Firm | Representing RSB SpineSearch in Eureka ↗ |
| Plaintiff law firm | Snell & Wilmer, LLP | Law Firm | Representing RSB SpineSearch in Eureka ↗ |
| Presiding judge | Judge David Barlow | Judge | Utah District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i), which permits a plaintiff to exit before any responsive pleading. The critical qualifier — ‘with prejudice’ — is self-imposed by RSB Spine and carries the full weight of a merits adjudication for claim-preclusion purposes. This phrasing permanently extinguishes RSB Spine’s infringement claims against Innovasis under US9713537B2. The absence of any court-ordered terms, fee award, or disclosed consideration is typical of negotiated exits at this stage, where parties prefer confidentiality over public resolution.
US9713537B2 — Spinal Fusion Implant Technology (ALIF System)
US9713537B2, filed under application number US15/413945, protects innovations in spinal fusion implant design — specifically technology relevant to stand-alone anterior lumbar interbody fusion systems. ALIF procedures access the lumbar spine from the front of the body and place an implant between vertebrae to promote fusion. Stand-alone ALIF systems are notable for integrating fixation elements directly into the implant body, eliminating the need for supplemental posterior instrumentation. The patent’s claims in this domain carry significant commercial weight given the premium pricing and surgical adoption of ALIF procedures.
From a competitive intelligence standpoint, US9713537B2 represents a meaningful IP asset in a market where design differentiation and biomechanical performance are tightly contested. RSB Spine’s decision to enforce the patent against Innovasis’s Ax® system — a product positioned directly in the stand-alone ALIF segment — reflects deliberate portfolio monetisation. For other device makers developing or commercialising ALIF implants, the active status of this patent post-litigation makes it a priority asset to map against their own product claims.
Should you run an FTO against US9713537B2 for your ALIF product?
Any company developing, manufacturing, or distributing stand-alone anterior lumbar interbody fusion systems should treat US9713537B2 as a priority FTO target. This case confirms the patent is actively enforced: RSB Spine retained major litigation counsel and filed suit within the District of Utah against a direct competitor. The patent has not been invalidated, disclaimed, or challenged through IPR in this proceeding, meaning its claims stand at full strength against the market.
PatSnap Eureka’s FTO Search Agent enables R&D and regulatory teams to map product features against the claim language of US9713537B2 in hours rather than weeks. Eureka surfaces cited prior art, identifies claim scope boundaries, and flags design-around opportunities — helping medical device teams make go/no-go decisions with patent risk data built in from the earliest stages of product development.
Run a freedom-to-operate analysis on US9713537B2 to assess your product’s exposure
Run FTO in Eureka →Similar Spinal Implant Patent Cases in U.S. District Courts
Explore comparable ALIF and spinal fusion device patent infringement actions filed in Utah and other federal district courts, including outcomes and enforcement patterns.
What this case signals for the spinal implant IP landscape
A fast, finality-carrying exit in Utah spinal device litigation deserves careful reading by any competitor in the interbody fusion space.
With-prejudice exits in under six months nearly always signal value exchange
When a plaintiff voluntarily dismisses with prejudice before any substantive hearing, it typically means something moved — a payment, a license, or a commercial agreement. RSB Spine’s use of Proskauer Rose signals this was not a resource-constrained retreat. Companies competing in the ALIF segment should assume a confidential deal was reached and monitor for any licensing program that follows.
US9713537B2 remains live — other ALIF manufacturers are not protected
The dismissal binds only RSB Spine’s claims against Innovasis. The patent itself is unaffected, unchallenged, and fully enforceable against the rest of the market. Any manufacturer of stand-alone ALIF systems or anterior lumbar interbody fusion implants with structural similarity to the claims should assess freedom-to-operate before assuming this outcome provides any cover.
Spine v Innovasis — key questions answered
The dismissal with prejudice ends RSB Spine’s infringement claims against Innovasis permanently but does not affect the patent’s validity or enforceability against other parties. US9713537B2 remains an active, enforceable patent that RSB Spine may assert against other ALIF system manufacturers. The case produced no invalidity ruling, no claim construction, and no public license terms.
The public record does not disclose the reason. However, voluntary dismissals with prejudice filed this early — before any answer or substantive motion — typically suggest either a confidential settlement with compensation to the plaintiff, or a strategic decision following pre-litigation due diligence. The involvement of Proskauer Rose makes a pure resource-driven withdrawal less likely.
RSB Spine’s complaint alleged that the Innovasis Ax® Stand-Alone ALIF System infringed US9713537B2, a patent covering anterior lumbar interbody fusion implant technology. Stand-alone ALIF systems integrate fixation directly into the implant, and the patent’s claims appear to cover design or structural features of that product category. No claim construction or infringement analysis was published before dismissal.
No. The with-prejudice dismissal is strictly bilateral — it bars RSB Spine from suing Innovasis again on US9713537B2 but provides no protection to third parties. Other manufacturers of competing stand-alone ALIF systems remain fully exposed to potential infringement claims under this patent. Companies in the ALIF segment should conduct independent freedom-to-operate analysis.
RSB Spine was represented by two firms: Proskauer Rose, LLP — a nationally prominent IP litigation practice — and Snell & Wilmer, LLP, a leading regional firm with strong Utah presence. Individual attorneys of record included Baldassare Vinti, Erik B. Milch, Joseph M. Drayton, Elizabeth Shrieves, Mark O. Morris, and Sarah W. Ghivizzani. No defendant counsel was listed in the public case record.
PatSnap Eureka searches patents and litigation data to answer instantly.